Fluzoparib

Generic Name: Fluzoparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₆F_₄N_₆O_₂

CAS Number: 1358715-18-0

Unique Ingredient Identifier: TWF0ML1CK8

Background: Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).

Indication: ⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Phase 2

Not yet recruiting

Conditions: Relapsed Ovarian Cancer

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Jin Li

Target Recruit Count: 54

Registration Number: NCT06081595

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Fluzoparib
Radiation: Preoperative moderately fractionated radiotherapay

First Posted Date: 2023-07-10

Last Posted Date: 2023-07-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 100

Registration Number: NCT05938374

Locations: 🇨🇳
Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical Center, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma,Soft Tissue
Brachytherapy
Poly(ADP-ribose) Polymerase Inhibitors

Interventions: Drug: Fluzoparib
Procedure: Radioactive particle implantation

First Posted Date: 2023-06-08

Last Posted Date: 2023-07-25

Lead Sponsor: Fujun Zhang

Target Recruit Count: 32

Registration Number: NCT05894018

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Fluzoparib
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen
Drug: Toremifene
Drug: Abemaciclib
Drug: LHRH agonist

First Posted Date: 2023-06-06

Last Posted Date: 2024-02-08

Lead Sponsor: Fudan University

Target Recruit Count: 766

Registration Number: NCT05891093

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangdong, Guangzhou, China
🇨🇳
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 12 locations

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

Phase 2

Recruiting

Conditions: Her-2 Negative Breast Cancer
HRR Gene Mutation

Interventions: Drug: Camrelizumab
Drug: Fluzoparib
Drug: Nab-paclitaxel

First Posted Date: 2023-03-09

Last Posted Date: 2023-03-09

Lead Sponsor: Ying Lin

Target Recruit Count: 66

Registration Number: NCT05761470

Locations: 🇨🇳
First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer Metastatic

Interventions: Drug: Fluzoparib
Drug: Dalpiciclib
Drug: Fulvestrant/AI

First Posted Date: 2023-03-08

Last Posted Date: 2024-02-06

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT05759546

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Phase 2

Not yet recruiting

Conditions: Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer

Interventions: Drug: Fluzoparib
Drug: Irinotecan

First Posted Date: 2023-02-16

Last Posted Date: 2023-02-24

Lead Sponsor: Fudan University

Target Recruit Count: 29

Registration Number: NCT05732129

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Interventions: Drug: Fluzoparib+Camrelizumab
Drug: Fluzoparib

First Posted Date: 2022-12-19

Last Posted Date: 2023-01-31

Lead Sponsor: wang shusen

Target Recruit Count: 80

Registration Number: NCT05656131

Locations: 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Guangdong, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Fluzoparib
Biological: QL1101

First Posted Date: 2022-10-18

Last Posted Date: 2023-07-28

Lead Sponsor: Yongpeng Wang

Target Recruit Count: 25

Registration Number: NCT05585281

Locations: 🇨🇳
Yongpeng Wang, Shenyang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy